Pfizer Medical Presents a Webinar Series on COVID-19 and Pfizer’s authorized COVID-19 prescription oral treatment
This webinar focuses on reviewing high risk conditions associated with severe COVID-19 outcomes, medical educational resources available for health care providers on the Pfizer Medical Portal, and recent updates to the PAXLOVID Emergency Use Authorization (EUA) Fact Sheet for healthcare providers. The webinar series will also include a question-and-answer session that will give the audience an opportunity to ask internal Pfizer medical experts questions.
Identify population groups at risk of progression to severe COVID-19 including: obesity, diabetes, cancer, cardiovascular disease, increasing age, and others
Discuss recent updates to the PAXLOVID Fact Sheet for Healthcare Providers
Review COVID-19 and PAXLOVID medical educational resources available on the Pfizer Medical Portal: Pfizer Medical | Infectious Disease
All healthcare professionals including but not limited to physicians, nurse practitioners, pharmacists, and physician assistants
COVID-19: Focus on Obesity and Pfizer's authorized COVID-19 Treatment
PAXLOVID™ has not been approved, but has been authorized for emergency use by FDA under an EUA, for the treatment of mild-to-moderate COVID-19 in adults and pediatric patients (12 years of age and older weighing at least 40 kg) with positive results of direct SARS CoV-2 viral testing, and who are at high-risk for progression to severe COVID-19, including hospitalization or death.
The emergency use of PAXLOVID is only authorized for the duration of the declaration that circumstances exist justifying the authorization of the emergency use of drugs and biological products during the COVID-19 pandemic under Section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1), unless the declaration is terminated or authorization revoked sooner.